Really? I think it would be far better and cheaper for Healios to just continue to expand the partnership and keep our team in place, we don't need a buyout, we have the platform and the manufacturing, why would Gil and Company take a buyout, I don't see it being easily accomplished once PMDA approval is given, because it further validates the rest of the pipeline indications. It does beg the question, though, what is the depth of financial capability in Healios? Their quarterly report is now posted on their website as I posted earlier today, anyone? This Company Athersys is going to quickly become a several $billion company.
What is your opinion on timing now that Healios and Athersys have agreed on a more robust trial with perhaps 100-200 participants in as many as 4+ trial sites? Will there be an interim data readout that could qualify for PMDA conditional or full approval based on their new expedited laws for approval?
From the you tube video entitled "R and D Partnership Day", /watch?v=rviLNOExY0Q.
I love the statement by Hardy T.S. Kagimoto, President and Executive Director of Healios. "I think this is a moment we can create a company like Amgen or Genentech. What you need is... you have to be there at the birth of a new class of therapy, and this is a moment." If you haven't watched this video, it is a must see.
Moderator Jason Kolbert handles himself with great poise, skill and intellect, with considerable enthusiasm. "We're looking at the potential for Athersys to move at a pace that none of us seem to be expecting, certainly the value of the stock in the marketplace doesn't expect. And pending that data release, you could see MultiStem unlocked to become a very, very big product."
Athersys and Healios, "the potential to change medicine as we know it." Jason Kolbert.
"We think that by working together, we can achieve that." Dr. Gil Van Bakken
Longs, I had a bid for shares this afternoon at 2.18 and it didn't get filled. Mid morning I think it traded below $2.20 but not for long. Closing at 2.23 when yesterday we closed at 2.29. I'd like to see the floor set in concrete at 2.20, no closes below it, can we all agree not to let these HFT programs work it lower? I know it's hard to control, really we don't have any control, but think hard about that floor, and let's see if we can't will it to be. Enough of us thinking that and you might be surprised how effective a mind set can be. GLAL.
I see tomorrow is the 13th, uh oh. I don't believe in this day being bad, so let's hope we see something positive. I also see we may have another reversal on our hands, from mid session today with follow through tomorrow? The Dow Industrials and the S&P 500 both had reversals today as well off of the 50-dma's. That is a good sign, maybe these last three weeks are what was needed to go to all time highs? I'm not saying it is going to happen, actually it is against the odds IMHO
OK, don't look, remember? Interesting that both AVXL and MRNS have shed one third of their value (+-) from mid $6 range to $4/mid-$4 rangein the last 3 weeks. IBB is either going to test the January lows or break down altogether. XBI along with it. Hate this market. VA, I took a 51% profit out of GALE yesterday at $1.30 out.
Thanks Bourbon, confirming that for decades now the drugs were targeting the by-product and not "upstream" as Missling points out is the difference in approach used by Anavex. The market forces are thrashing our stock now but those who understand and keep their shares through all this nonsense will be thrilled in a few years with their decision.
Anything biotech is getting crushed this week. I traded out of HZNP this morning flat as I saw it heading toward my basis. Across the board today down big, ETF's IBB and XBI are approaching their January lows. This sector isn't a friendly place to be this year. The last three weeks have been especially brutal. I also sold my GALE shares yesterday for a nice 50%+ profit. There have been few profits this year, that was an obvious one to take. We need more than good luck
On the landing page on their website wwwDOThealiosDOTcoDOTjp/en you will find they added their first quarter report of financial condition and update, which you can download in PDF. Athersys is prominently visible throughout as we are now a very important partner in their game plan, clearly their vision is worldly, as you will see. It's clear now to understand the enormous potential once you pour over this report.
The US markets are so manipulated, it's getting to the point of why bother investing, particularly in any market that isn't an outright bull. Shorts are killing the biotech sector, innovation will end if they continue. Too many companies are being forced out of business, their stocks have been so brutally shorted.
"Healios will, in addition to the compound drug field, position ourselves as a core company in the field of regenerative medicine products that utilize iPS cell technologies. We will build cooperative relationships with leading research institutes, universities and businesses around the world for the research and development of drugs and regenerative medicine products." wwwDOThealiosDOTcoDOTjp/en/message/transition/
As regards the expansion of the partnership to include other indications, and other markets, watching the videos carefully, taking the many statements offered by Gil and Hardy, and projecting their own vision statement forward, the likelihood of Athersys becoming fully integrated as a worldwide partner of Healios seems more than likely, just a question of time IMHO.
BIOC is being shorted into oblivion, but why does the market allow this? There aren't enough buyers to stave off the short attack in any one day. TROV stock is doing better, it was up after hours today .35, after their new CEO presented their Q1 results.
Feels like a warning and this time I am not going to hold through data release after CLDX. I have a 61% profit now and they aren't expected to release data until end of Q1 so there remains a run up to data. I plan to take profits this time thanks.
2 LIFESCAN SCOTLAND, LTD. v. PHARMATECH SOLUTIONS, INC.
and thereafter the petition for rehearing en banc was
referred to the circuit judges who are in regular active
Upon consideration thereof,
IT IS ORDERED THAT:
The petition for panel rehearing is denied.
The petition for rehearing en banc is denied.
The mandate of the court will issue May 17, 2016.
FOR THE COURT
May 10, 2016 /s/ Peter R. Marksteiner
Date Peter R. Marksteiner
Clerk of Court
Another partial link for Youtube video that imho is a can't miss video only 4 minutes. Jason Kolbert present in video, also Healios and Athersys.
/watch?v=rviLNOExY0Q Put link in youtube search window after their domain.
Sentiment: Strong Buy
Thanks for weighing in on this discussion weasl. Yahoo misplaced my post in reply, look above to see my reply today as regards these positions in Gale and Athx. Thx.
weasl, I appreciate your view, now let me address the ATHX subject. /watch?v=Ft-lSv5eSbw The partial link can be placed in the search window on youtube to take you to Jason Kolbert's interview of Dr. Gil VanBakken, CEO of Athersys March 22, 2016. I think this is a compelling opportunity to shareholders of ATHX with MultiStem's 36 hour window to treat Ischemic stroke in Japan and the ROW. Healios agrees, they put up the $15MM to partner with ATHX for rights to Japan for IS, 339,000 first strokes every year in Japan. Reimbursement rates around $100K per patient. Athersys also has phase 2 trials in ARDS (acute respiratory distress syndrome) and myocardial infarction. Healios may yet partner these other indications. They are paying for the robust IS trial in planning now.
GALE is another story, I won't hold through the data release likely.
The stock hasn't had a white candle for almost three weeks straight. The last 14 trading days we've either had a red candle, a black candle, or a doji candle. The black candles occur when the MM opens higher than the previous day's close and the shorts push it down below the open. We've lost a lot of ground since they announced the offering. The earnings call may contain a positive surprise that will boost the stock, let's hope.
Gaps down and back up not filled yet, gap remains between 14.16 to 14.41. Gaps fill 91% of the time. Your thought is pleasing to longs but not accurate, nor realistic given what this stock has been through and the reluctance of the short trade to cover. The Q1 report certainly justifies your view though.